ARA-C AND AMSA IN THE THERAPY OF RELAPSED AND REFRACTORY ACUTE MYELOID-LEUKEMIA

被引：0
|
作者：
JAGER, U [1 ]
机构：
[1] VIENNA UNIV,MED KLIN 1,A-1010 VIENNA,AUSTRIA
来源：
WIENER KLINISCHE WOCHENSCHRIFT | 1986年 / 98卷 / 17期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：589 / 589
页数：1
相关论文
共 50 条
  • [21] TREATMENT OF RELAPSED AND REFRACTORY ACUTE MYELOID-LEUKEMIA IN ADULTS
    LAZZARINO, M
    MORRA, E
    ALESSANDRINO, EP
    MERANTE, S
    BERNASCONI, P
    BONFICHI, M
    CALDERA, D
    BERNASCONI, C
    BONE MARROW TRANSPLANTATION, 1989, 4 : 121 - 123
  • [22] THE MANAGEMENT OF RELAPSED AND REFRACTORY ACUTE MYELOID-LEUKEMIA IN ADULTS
    JONES, L
    NEWLAND, AC
    LEUKEMIA & LYMPHOMA, 1991, 4 (02) : 93 - 98
  • [23] IDARUBICIN IN THE TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID-LEUKEMIA
    HAROUSSEAU, JL
    HURTELOUP, P
    REIFFERS, J
    RIGALHUGUET, F
    HAYAT, M
    DUFOUR, P
    LEPRISE, PY
    MONCONDUIT, M
    JAUBERT, J
    CARCASSONNE, Y
    CANCER TREATMENT REPORTS, 1987, 71 (10): : 991 - 992
  • [24] ETOPOSIDE (VP-16) AND CYTOSINE-ARABINOSIDE (ARA-C) COMBINATION FOR SECONDARY AND RELAPSED ACUTE MYELOID-LEUKEMIA (AML)
    LAZZARINO, M
    MORRA, E
    INVERARDI, D
    ALESSANDRINO, EP
    BERNASCONI, P
    MERANTE, S
    BERNASCONI, C
    LEUKEMIA RESEARCH, 1986, 10 (01) : 111 - 111
  • [25] PHARMACOLOGICALLY DIRECTED ARA-C THERAPY FOR REFRACTORY LEUKEMIA
    PLUNKETT, W
    IACOBONI, S
    ESTEY, E
    DANHAUSER, L
    LILIEMARK, JO
    KEATING, MJ
    SEMINARS IN ONCOLOGY, 1985, 12 (02) : 20 - 30
  • [26] DAE (DAUNORUBICIN, ARA-C, AND ETOPOSIDE) AND INTERMEDIATE DOSE ARA-C FOR REMISSION INDUCTION AND CONSOLIDATION TREATMENT OF ADULT PATIENTS WITH ACUTE MYELOID-LEUKEMIA
    HWANG, WL
    YOUNG, JH
    GAU, JP
    HU, HT
    TSAI, YT
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1992, 15 (06): : 531 - 534
  • [27] Treatment with high dose Ara-C and Topotecan for relapsed/refractory acute myelogenous leukemia (AML).
    Case, DC
    Ebrahim, KS
    Aronson, FR
    Hedlund, JA
    BLOOD, 2000, 96 (11) : 209B - 209B
  • [28] Idarubicin and intermediate dose ARA-C followed by consolidation chemotherapy or bone marrow transplantation in relapsed or refractory acute myeloid leukemia
    DelaSerna, J
    Tomas, JF
    Solano, C
    DeParedes, MLG
    Campbell, J
    Grande, C
    DiazMediavilla, J
    LEUKEMIA & LYMPHOMA, 1997, 25 (3-4) : 365 - 372
  • [29] CYTOSINE-ARABINOSIDE (ARA-C) IN INTERMEDIATE DOSES (IDAC) AS THERAPY FOR PATIENTS (PTS) WITH ACUTE MYELOID-LEUKEMIA (AML)
    ESTEY, EH
    PLUNKETT, WK
    KEATING, MJ
    MCCREDIE, KB
    FREIREICH, EJ
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 209 - 209
  • [30] LONG-TERM RESULTS IN ACUTE MYELOID-LEUKEMIA TREATED WITH CONVENTIONAL DAUNORUBICIN, ARA-C (DA) AND THIOGUANINE, ARA-C, DAUNORUBICIN (TAD) POLYCHEMOTHERAPY
    FREUND, M
    LINK, H
    BODENSTEIN, H
    POLIWODA, H
    BLUT, 1986, 53 (03): : 241 - 241
12345